Functional assessment of rat pulmonary flavin-containing monooxygenase activity

References

• Aoki M, Okudaira K, Haga M, et al. (2010). Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. Drug Metab Dispos 38:1183–8.
   PubMed Web of Science ®Google Scholar
• Capolongo F, Santi A, Anfossi P, Montesissa C. (2010). Benzydamine as a useful substrate of hepatic flavin-containing monooxygenase activity in veterinary species. J Vet Pharmacol Ther 33:341–6.
   PubMed Web of Science ®Google Scholar
• Carlile DJ, Hakooz N, Houston JB. (1999). Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. Drug Metab Dispos 27:526–32.
   PubMed Web of Science ®Google Scholar
• Cashman JR. (2005). Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:599–604.
   PubMed Web of Science ®Google Scholar
• Cashman JR, Zhang J. (2006). Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65–100.
   PubMed Web of Science ®Google Scholar
• Cassidy MK, Houston JB. (1980). In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol. J Pharm Pharmacol 32:57–9.
   PubMed Web of Science ®Google Scholar
• Cherrington NJ, Cao Y, Cherrington JW, et al. (1998). Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5. Xenobiotica 28:673–82.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
   PubMed Web of Science ®Google Scholar
• De Graaf IA, De Kanter R, De Jager MH, et al. (2006). Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 34:591–9.
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky LS. (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–73.
   PubMed Web of Science ®Google Scholar
• Dolphin C, Shephard EA, Povey S, et al. (1991). Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FMO1). J Biol Chem 266:12379–85.
   PubMed Web of Science ®Google Scholar
• Dolphin CT, Beckett DJ, Janmohamed A, et al. (1998). The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem 273:30599–607.
   PubMed Web of Science ®Google Scholar
• Dolphin CT, Cullingford TE, Shephard EA, et al. (1996). Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. Eur J Biochem 235:683–9.
   PubMedGoogle Scholar
• Dolphin CT, Janmohamed A, Smith RL, et al. (1997). Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet 17:491–4.
   PubMed Web of Science ®Google Scholar
• Ekins S, Murray GI, Burke MD, et al. (1995). Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metab Dispos 23:1274–9.
   PubMed Web of Science ®Google Scholar
• Falls JG, Blake BL, Cao Y, et al. (1995). Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice. J Biochem Toxicol 10:171–7.
   PubMedGoogle Scholar
• Fiorentini F, Romero E, Fraaije MW, et al. (2017). Baeyer–Villiger monooxygenase FMO5 as entry point in drug metabolism. ACS Chem Biol 12:2379–87.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Yoon K, Vaughn ML, et al. (2002). Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 30:1087–93.
   PubMed Web of Science ®Google Scholar
• Furnes B, Schlenk D. (2004). Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol Sci 78:196–203.
   PubMed Web of Science ®Google Scholar
• Geier M, Bachler T, Hanlon SP, et al. (2015). Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microbial Cell Fact 14:82.
   PubMed Web of Science ®Google Scholar
• Gundert-Remy U, Bernauer U, Blömeke B, et al. (2014). Extrahepatic metabolism at the body’s internal–external interfaces. Drug Metab Rev 46:291–324.
   PubMed Web of Science ®Google Scholar
• Henderson MC, Krueger SK, Siddens LK, et al. (2004). S-oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. Biochem Pharmacol 68:959–67.
   PubMed Web of Science ®Google Scholar
• Henderson MC, Siddens LK, Morré JT, et al. (2008). Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Toxicol Appl Pharmacol 233:420–7.
   PubMed Web of Science ®Google Scholar
• Hines RN. (2006). Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert Opin Drug Metab Toxicol 2:41–9.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Zientek MA. (2016). Non-cytochrome P450 enzymes and glucuronidation. In New horizons in predictive drug metabolism and pharmacokinetics. Washington (DC): The Royal Society of Chemistry, 79–130.
   Google Scholar
• Itoh K, Kimura T, Yokoi T, et al. (1993). Rat liver flavin-containing monooxygenase (FMO): cDNA cloning and expression in yeast. Biochim Biophys Acta 1173:165–71.
   PubMedGoogle Scholar
• Janmohamed A, Hernandez D, Phillips IR, Shephard EA. (2004). Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (FMOs). Biochem Pharmacol 68:73–83.
   PubMed Web of Science ®Google Scholar
• Jhajra S, Ramesh Varkhede N, Suresh Ahire D, et al. (2012). Extrahepatic drug-metabolizing enzymes and their significance. Encyclopedia Drug Metab Interact. [Epub ahead of print]. doi:10.1002/9780470921920.edm028.
   Google Scholar
• Jones BC, Srivastava A, Colclough N, et al. (2017). An investigation into the prediction of in vivo clearance for a range of flavin-containing monooxygenase substrates. Drug Metab Dispos 45:1060–7.
   PubMed Web of Science ®Google Scholar
• Karoly ED, Rose RL. (2001). Sequencing, expression, and characterization of cDNA expressed flavin-containing monooxygenase 2 from mouse. J Biochem Molecul Toxicol 15:300–8.
   PubMed Web of Science ®Google Scholar
• Kawaji A, Ohara K, Takabatake E. (1993). An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation. Anal Biochem 214:409–12.
   PubMed Web of Science ®Google Scholar
• Koukouritaki SB, Simpson P, Yeung CK, et al. (2002). Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236–43.
   PubMed Web of Science ®Google Scholar
• Krueger SK, Siddens LK, Martin SR, et al. (2004). Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent. Drug Metab Dispos 32:1337–40.
   PubMed Web of Science ®Google Scholar
• Krueger SK, Yueh M-F, Martin SR, et al. (2001). Characterization of expressed full-length and truncated FMO2 from rhesus monkey. Drug Metab Dispos 29:693–700.
   PubMed Web of Science ®Google Scholar
• Lai WG, Farah N, Moniz GA, Wong YN. (2010). A Baeyer–Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61–70.
   PubMed Web of Science ®Google Scholar
• Lang DH, Rettie AE. (2000). In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 50:311–4.
   PubMed Web of Science ®Google Scholar
• Lattard V, Buronfosse T, Lachuer J, et al. (2001). Cloning, sequencing, tissue distribution, and heterologous expression of rat flavin-containing monooxygenase 3. Arch Biochem Biophys 391:30–40.
   PubMed Web of Science ®Google Scholar
• Lattard V, Lachuer J, Buronfosse T, et al. (2002a). Physiological factors affecting the expression of FMO1 and FMO3 in the rat liver and kidney. Biochem Pharmacol 63:1453–64.
   PubMed Web of Science ®Google Scholar
• Lattard V, Longin-Sauvageon C, Krueger SK, et al. (2002b). The FMO2 gene of laboratory rats, as in most humans, encodes a truncated protein. Biochem Biophys Res Commun 292:558–63.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Cashman JR, Cresteil T, et al. (1994). A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 308:254–7.
   PubMed Web of Science ®Google Scholar
• Meng J, Zhong D, Li L, et al. (2015). Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos 43:646–59.
   PubMed Web of Science ®Google Scholar
• Moroni P, Longin-Sauvageon C, Benoit E. (1995). The flavin-containing monooxygenases in rat liver: evidence for the expression of a second form different from FMO1. Biochem Biophys Res Commun 212:820–6.
   PubMed Web of Science ®Google Scholar
• Njuguna NM, Umehara KI, Huth F, et al. (2016). Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metab Pers Ther 31:221–8.
   PubMedGoogle Scholar
• Obach RS. (2001). The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Dev 4:36–44.
   PubMedGoogle Scholar
• Phillips IR, Dolphin CT, Clair P, et al. (1995). The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact 96:17–32.
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. (2017). Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13:167–81.
   PubMed Web of Science ®Google Scholar
• Rawden HC, Kokwaro GO, Ward SA, Edwards G. (2000). Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49:313–22.
   PubMed Web of Science ®Google Scholar
• Rettie AE, Meier GP, Sadeque AJ. (1995). Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 96:3–15.
   PubMed Web of Science ®Google Scholar
• Ripp SL, Itagaki K, Philpot RM, Elfarra AA. (1999). Species and sex differences in expression of flavin-containing monooxygenase form 3 in liver and kidney microsomes. Drug Metab Dispos 27:46–52.
   PubMed Web of Science ®Google Scholar
• Schmitz A, Portier CJ, Thormann W, et al. (2008). Stereoselective biotransformation of ketamine in equine liver and lung microsomes. J Vet Pharmacol Ther 31:446–55.
   PubMed Web of Science ®Google Scholar
• Scientific Procedures Act. (1986). Animals (Scientific Procedures) Act 1986. Available at: https://www.legislation.gov.uk/ukpga/1986/14/contents.
   Google Scholar
• Sharan S, Nagar S. (2013). Pulmonary metabolism of resveratrol: in vitro and in vivo evidence. Drug Metab Dispos 41:1163–9.
   PubMed Web of Science ®Google Scholar
• Störmer E, Roots I, Brockmöller J. (2000). Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553–61.
   PubMed Web of Science ®Google Scholar
• Taniguchi-Takizawa T, Shimizu M, Kume T, Yamazaki H. (2015). Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. Drug Metab Pharmacokin 30:64–9.
   PubMed Web of Science ®Google Scholar
• Tugnait M, Hawes EM, Mckay G, et al. (1997). N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 25:524–7.
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Yueh MF, Hopp KA, et al. (2000). Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216–24.
   PubMed Web of Science ®Google Scholar
• Worboys PD, Bradbury A, Houston JB. (1997). Kinetics of drug metabolism in rat liver slices: III. Relationship between metabolic clearance and slice uptake rate. Drug Metab Dispos 25:460–7.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Shimizu M, Uno Y, Yamazaki H. (2014). Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochem Pharmacol 90:159–65.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, et al. (2008). Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 36:1119–25.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Umehara K, Williams G, et al. (2017). Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat. Xenobiotica, 1–11. [Epub ahead of print]. doi:10.1080/00498254.2017.1373311.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cashman JR. (2005). Quantitative analysis of fmo gene mrna levels in human tissues. Drug Metab Dispos 34:19–26.
   PubMed Web of Science ®Google Scholar
• Ziegler DM. (1980). Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds A2. In: Jakoby WB, ed. Enzymatic basis of detoxication. New York (NY): Academic Press, 201–227.
   Google Scholar